Crestline Management LP Makes New $4.12 Million Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Crestline Management LP acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 33,893 shares of the biotechnology company's stock, valued at approximately $4,121,000.

A number of other hedge funds have also recently bought and sold shares of the company. Capital International Investors lifted its stake in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Norges Bank acquired a new position in Sarepta Therapeutics during the 4th quarter valued at about $126,315,000. Alkeon Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 34.7% in the 4th quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company's stock valued at $103,819,000 after purchasing an additional 220,000 shares during the last quarter. Brandywine Global Investment Management LLC acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $22,613,000. Finally, Northern Trust Corp raised its stake in shares of Sarepta Therapeutics by 22.6% during the fourth quarter. Northern Trust Corp now owns 803,511 shares of the biotechnology company's stock worth $97,699,000 after buying an additional 147,874 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Down 0.7 %

NASDAQ:SRPT traded down $0.25 during mid-day trading on Friday, hitting $36.27. 6,614,378 shares of the company's stock were exchanged, compared to its average volume of 1,621,069. Sarepta Therapeutics, Inc. has a fifty-two week low of $35.46 and a fifty-two week high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $3.56 billion, a P/E ratio of 29.02 and a beta of 0.85. The company has a 50 day simple moving average of $66.84 and a 200-day simple moving average of $100.66.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 EPS. As a group, research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Royal Bank of Canada decreased their price objective on Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a research note on Wednesday. Guggenheim dropped their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research note on Wednesday. HC Wainwright lowered their price objective on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a report on Wednesday. Wells Fargo & Company dropped their target price on Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a report on Thursday. Finally, Cantor Fitzgerald decreased their target price on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating on the stock in a research report on Wednesday. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $131.22.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.